Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in DRMA held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 48K | $58K | — | 7.092% | 0.00% |
| 2 | UBS Group AG | 36K | $43K | +2778.6% | 5.224% | 0.00% |
| 3 | WELCH & FORBES LLC | 20K | $24K | — | 2.934% | 0.00% |
| 4 | MCF Advisors LLC | 2K | $2K | — | 0.254% | 0.00% |
| 5 | Tower Research Capital LLC (TRC) | 716 | $866 | -64.2% | 0.105% | 0.00% |
| 6 | SBI Securities Co., Ltd. | 101 | $122 | 0.0% | 0.015% | 0.00% |
| 7 | CITIGROUP INC | 1 | $1 | — | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DRMA — a direct measure of their conviction.
Filings activity in DRMA during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 7 | +0.0% | 16.02% | +8.26 pp | $0M | +107% |
| Q4 2025 | 7 | +40% | 7.76% | 49.81 pp | $0M | 87% |
| Q3 2025 | 5 | 55% | 57.57% | +20.58 pp | $0M | +56% |
| Q2 2025 | 11 | +22% | 36.99% | 32.54 pp | $0M | 47% |
| Q1 2025 | 9 | +29% | 69.53% | +61.89 pp | $1M | +810% |
| Q4 2024 | 7 | +40% | 7.64% | +6.33 pp | $0M | +482% |
| Q3 2024 | 5 | 29% | 1.31% | 8.05 pp | $0M | 86% |
| Q2 2024 | 7 | — | 9.36% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying DRMA stock.
Based on Q1 2026 13F filings, institutional ownership of Dermata Therapeutics, Inc. stands at 16.0%, held across 7 reporting institutions.
GEODE CAPITAL MANAGEMENT, LLC is the largest reported institutional holder of DRMA, with approximately 48,334 shares worth $0.00B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of DRMA.
Our composite Smart Money Score for DRMA is 47 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
4 institutions opened new positions in DRMA during Q1 2026, while 4 fully exited. 1 added to existing positions and 2 trimmed.
DRMA institutional ownership rose by 8.26 percentage points quarter-over-quarter, with a net change of +0 holders.
The top 10 institutions account for 100.0% of all reported 13F value in DRMA, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Dermata Therapeutics, Inc. (DRMA) Institutional Ownership